Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia

M. R. Kibbe, A. T. Hirsch, F. O. Mendelsohn, M. G. Davies, H. Pham, J. Saucedo, W. Marston, W. B. Pyun, S. K. Min, B. G. Peterson, A. Comerota, Donghoon Choi, J. Ballard, R. A. Bartow, D. W. Losordo, W. Sherman, V. Driver, E. C. Perin

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

VM202, a plasmid DNA that expresses two isoforms of hepatocyte growth factor, may elicit angiogenic effects that could benefit patients with critical limb ischemia (CLI). In a phase 2, double-blind trial in 52 CLI patients, we examined the safety and potential efficacy of intramuscular injections of low-dose (n=21) or high-dose (n=20) VM202 or placebo (n=11) in the affected limb (days 0, 14, 28 and 42). Adverse events and serious adverse events were similar among the groups; no malignancy or proliferative retinopathy was seen. In exploratory efficacy analyses, we found no differences in ankle or toe-brachial index, VAS, VascuQuol or amputation rate among the groups. Complete ulcer healing was significantly better in high-dose (8/13 ulcers; P<0.01) versus placebo (1/9) patients. Clinically meaningful reductions (>50%) in ulcer area occurred in high-dose (9/13 ulcers) and low-dose (19/27) groups versus placebo (1/9; P<0.05 and P<0.005, respectively). At 12 months, significant differences were seen in TcPO 2 between the high-dose and placebo groups (47.5±17.8 versus 36.6±24.0 mm Hg, respectively; P<0.05) and in the change from baseline among the groups (P<0.05). These data suggest that VM202 is safe and may provide therapeutic bioactivity in CLI patients.

Original languageEnglish
Pages (from-to)306-312
Number of pages7
JournalGene Therapy
Volume23
Issue number3
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

Hepatocyte Growth Factor
Ulcer
Protein Isoforms
Plasmids
Ischemia
Extremities
Safety
DNA
Placebos
Ankle Brachial Index
Intramuscular Injections
Patient Safety
Amputation
Ankle
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Kibbe, M. R., Hirsch, A. T., Mendelsohn, F. O., Davies, M. G., Pham, H., Saucedo, J., ... Perin, E. C. (2016). Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia. Gene Therapy, 23(3), 306-312. https://doi.org/10.1038/gt.2015.110
Kibbe, M. R. ; Hirsch, A. T. ; Mendelsohn, F. O. ; Davies, M. G. ; Pham, H. ; Saucedo, J. ; Marston, W. ; Pyun, W. B. ; Min, S. K. ; Peterson, B. G. ; Comerota, A. ; Choi, Donghoon ; Ballard, J. ; Bartow, R. A. ; Losordo, D. W. ; Sherman, W. ; Driver, V. ; Perin, E. C. / Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia. In: Gene Therapy. 2016 ; Vol. 23, No. 3. pp. 306-312.
@article{dd69874f05c8497caf9ddfcb5193c092,
title = "Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia",
abstract = "VM202, a plasmid DNA that expresses two isoforms of hepatocyte growth factor, may elicit angiogenic effects that could benefit patients with critical limb ischemia (CLI). In a phase 2, double-blind trial in 52 CLI patients, we examined the safety and potential efficacy of intramuscular injections of low-dose (n=21) or high-dose (n=20) VM202 or placebo (n=11) in the affected limb (days 0, 14, 28 and 42). Adverse events and serious adverse events were similar among the groups; no malignancy or proliferative retinopathy was seen. In exploratory efficacy analyses, we found no differences in ankle or toe-brachial index, VAS, VascuQuol or amputation rate among the groups. Complete ulcer healing was significantly better in high-dose (8/13 ulcers; P<0.01) versus placebo (1/9) patients. Clinically meaningful reductions (>50{\%}) in ulcer area occurred in high-dose (9/13 ulcers) and low-dose (19/27) groups versus placebo (1/9; P<0.05 and P<0.005, respectively). At 12 months, significant differences were seen in TcPO 2 between the high-dose and placebo groups (47.5±17.8 versus 36.6±24.0 mm Hg, respectively; P<0.05) and in the change from baseline among the groups (P<0.05). These data suggest that VM202 is safe and may provide therapeutic bioactivity in CLI patients.",
author = "Kibbe, {M. R.} and Hirsch, {A. T.} and Mendelsohn, {F. O.} and Davies, {M. G.} and H. Pham and J. Saucedo and W. Marston and Pyun, {W. B.} and Min, {S. K.} and Peterson, {B. G.} and A. Comerota and Donghoon Choi and J. Ballard and Bartow, {R. A.} and Losordo, {D. W.} and W. Sherman and V. Driver and Perin, {E. C.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1038/gt.2015.110",
language = "English",
volume = "23",
pages = "306--312",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "3",

}

Kibbe, MR, Hirsch, AT, Mendelsohn, FO, Davies, MG, Pham, H, Saucedo, J, Marston, W, Pyun, WB, Min, SK, Peterson, BG, Comerota, A, Choi, D, Ballard, J, Bartow, RA, Losordo, DW, Sherman, W, Driver, V & Perin, EC 2016, 'Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia', Gene Therapy, vol. 23, no. 3, pp. 306-312. https://doi.org/10.1038/gt.2015.110

Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia. / Kibbe, M. R.; Hirsch, A. T.; Mendelsohn, F. O.; Davies, M. G.; Pham, H.; Saucedo, J.; Marston, W.; Pyun, W. B.; Min, S. K.; Peterson, B. G.; Comerota, A.; Choi, Donghoon; Ballard, J.; Bartow, R. A.; Losordo, D. W.; Sherman, W.; Driver, V.; Perin, E. C.

In: Gene Therapy, Vol. 23, No. 3, 01.03.2016, p. 306-312.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia

AU - Kibbe, M. R.

AU - Hirsch, A. T.

AU - Mendelsohn, F. O.

AU - Davies, M. G.

AU - Pham, H.

AU - Saucedo, J.

AU - Marston, W.

AU - Pyun, W. B.

AU - Min, S. K.

AU - Peterson, B. G.

AU - Comerota, A.

AU - Choi, Donghoon

AU - Ballard, J.

AU - Bartow, R. A.

AU - Losordo, D. W.

AU - Sherman, W.

AU - Driver, V.

AU - Perin, E. C.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - VM202, a plasmid DNA that expresses two isoforms of hepatocyte growth factor, may elicit angiogenic effects that could benefit patients with critical limb ischemia (CLI). In a phase 2, double-blind trial in 52 CLI patients, we examined the safety and potential efficacy of intramuscular injections of low-dose (n=21) or high-dose (n=20) VM202 or placebo (n=11) in the affected limb (days 0, 14, 28 and 42). Adverse events and serious adverse events were similar among the groups; no malignancy or proliferative retinopathy was seen. In exploratory efficacy analyses, we found no differences in ankle or toe-brachial index, VAS, VascuQuol or amputation rate among the groups. Complete ulcer healing was significantly better in high-dose (8/13 ulcers; P<0.01) versus placebo (1/9) patients. Clinically meaningful reductions (>50%) in ulcer area occurred in high-dose (9/13 ulcers) and low-dose (19/27) groups versus placebo (1/9; P<0.05 and P<0.005, respectively). At 12 months, significant differences were seen in TcPO 2 between the high-dose and placebo groups (47.5±17.8 versus 36.6±24.0 mm Hg, respectively; P<0.05) and in the change from baseline among the groups (P<0.05). These data suggest that VM202 is safe and may provide therapeutic bioactivity in CLI patients.

AB - VM202, a plasmid DNA that expresses two isoforms of hepatocyte growth factor, may elicit angiogenic effects that could benefit patients with critical limb ischemia (CLI). In a phase 2, double-blind trial in 52 CLI patients, we examined the safety and potential efficacy of intramuscular injections of low-dose (n=21) or high-dose (n=20) VM202 or placebo (n=11) in the affected limb (days 0, 14, 28 and 42). Adverse events and serious adverse events were similar among the groups; no malignancy or proliferative retinopathy was seen. In exploratory efficacy analyses, we found no differences in ankle or toe-brachial index, VAS, VascuQuol or amputation rate among the groups. Complete ulcer healing was significantly better in high-dose (8/13 ulcers; P<0.01) versus placebo (1/9) patients. Clinically meaningful reductions (>50%) in ulcer area occurred in high-dose (9/13 ulcers) and low-dose (19/27) groups versus placebo (1/9; P<0.05 and P<0.005, respectively). At 12 months, significant differences were seen in TcPO 2 between the high-dose and placebo groups (47.5±17.8 versus 36.6±24.0 mm Hg, respectively; P<0.05) and in the change from baseline among the groups (P<0.05). These data suggest that VM202 is safe and may provide therapeutic bioactivity in CLI patients.

UR - http://www.scopus.com/inward/record.url?scp=84960128755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960128755&partnerID=8YFLogxK

U2 - 10.1038/gt.2015.110

DO - 10.1038/gt.2015.110

M3 - Article

VL - 23

SP - 306

EP - 312

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 3

ER -